Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Interventional, Multicenter, Single Arm, Phase I/IIa Clinical Trial to Investigate the Efficacy and Safety of Allo-APZ2-EB on Epidermolysis Bullosa (EB)

NCT03529877 is registered in ClinicalTrials.gov with RHEACELL GmbH & Co. KG as lead sponsor.

NCT NCT03529877
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03529877 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Interventional, Multicenter, Single Arm, Phase I/IIa Clinical Trial to Investigate the Efficacy and Safety of Allo-APZ2-EB on Epidermolysis Bullosa (EB)
Lead sponsor
RHEACELL GmbH & Co. KG
Phase
Phase 1/2
Overall status
Completed
Start date
February 16, 2019
Completion date
November 26, 2021
Enrollment
16 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

recessive dystrophic epidermolysis bullosa